At Nubia Capital, we are driven by a singular mission: to back visionary founders who are building essential infrastructure in underserved markets. Today, we are excited to announce our investment in Syndicate Bio, a cutting-edge precision medicine company developing the world’s richest and most diverse human genomic datasets, beginning with African populations.
Founded by Dr. Abasi Ene-Obong, Syndicate Bio is using genomics, multi-omics, AI/ML, and bioinformatics to unlock the next frontier of drug discovery, clinical trial efficiency, and personalized healthcare outcomes. The company is not only filling a critical data gap but also shaping the future of global medicine.
Syndicate Bio’s Approach
- Genomic Services: Clinical oncology testing, national precision medicine programs (e.g., Botswana Genomics).
- Licensing & AI Tools: Novel target discovery, biomarker identification, clinical trial optimization.
- Co-Development: Biopharma partnerships for milestone-based revenue and royalties.
With over 75 million novel genetic variants discovered and partnerships already in motion with governments and research institutions, Syndicate Bio is positioned to become a global leader in data-driven healthcare innovation.
Why This Matters
Africa is the most genetically diverse continent on Earth, yet less than 2.5% of global genomic data comes from African populations. This lack of representation limits the effectiveness and safety of many global therapeutics.
Syndicate Bio is solving this problem by building large-scale, ethically sourced genomic datasets and applying advanced AI and bioinformatics to extract valuable insights for drug development and clinical care. The impact is profound: faster trials, better drugs, more inclusive science, and ultimately, healthcare that works for everyone.
Strategic Alignment with Nubia Capital
Syndicate Bio aligns with Nubia Capital’s thesis around data infrastructure, deep tech, and systems innovation across the African continent and beyond. The team is building a long-term asset: a genomic and AI-powered platform that enables more effective therapeutics and equitable healthcare delivery worldwide.
“At Nubia Capital, we look for category-defining companies that not only solve big problems but reshape how systems work. Syndicate Bio is doing exactly that — bringing together deep science, high-quality data, and scalable technology to redefine how the world approaches precision medicine,” said Davidson Oturu, Managing Partner at Nubia Capital.
“Their work is not just about Africa — it’s about building an inclusive global health infrastructure that’s long overdue. We are excited to support Dr. Abasi and the Syndicate Bio team as they build the foundational genomic layer for the next generation of medicine.”
Looking Ahead
We believe Syndicate Bio is laying the groundwork for a healthier future — one where genetic diversity is valued, AI accelerates discovery, and every patient matters.
We’re proud to be on this journey with them.
About Nubia Capital
Nubia Capital is a venture capital firm investing in bold founders building transformative companies across Africa and global emerging markets. We back innovation in fintech, digital health, deep tech, and applied AI — with a focus on scalable systems that unlock inclusion, access, and infrastructure.tal.vc
